Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 14,938 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disease Clear all
Completed Phase 3 Interventional Results available

Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1

NCT02770716
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Terlipressin, Placebo
Drug · Other
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 22, 2026, 11:41 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Pediatric Appendicitis Risk Calculator (pARC) in Children With Appendix Ultrasounds

NCT03522233
View directory record Official record
Conditions
Appendicitis
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
5 Years to 18 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 22, 2026, 11:41 AM EDT
Completed No phase listed Observational

Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis

NCT00577252
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Akron Children's Hospital
Other
Eligibility
13 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2009 · Synced Oct 22, 2026, 11:41 AM EDT
Recruiting Phase 2 Interventional

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

NCT07685938
View directory record Official record
Conditions
Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions
Atorvastatin and Lisinopril, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 11:41 AM EDT
Recruiting No phase listed Observational

Endoscopic Submucosal Dissection (ESD)

NCT05468008
View directory record Official record
Conditions
Esophageal Lesion, Barrett Esophagus, Gastrointestinal Lesions
Interventions
Endoscopic Submucosal Dissection
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 22, 2026, 11:41 AM EDT
Terminated Phase 2 Interventional Results available

The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients

NCT00791076
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Pancreatic Polypeptide (PP)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 22, 2026, 11:41 AM EDT
Completed Not applicable Interventional

Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer

NCT02129218
View directory record Official record
Conditions
Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer, Stage I Rectal Cancer, Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions
questionnaire administration, laboratory biomarker analysis, Standard Dietary Intervention, Intensified Dietary Intervention, Low glycemic load, Medium Glycemic Load
Other · Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 22, 2026, 11:41 AM EDT
Completed Not applicable Interventional

Cold Therapy for Pediatric Appendectomy

NCT04986397
View directory record Official record
Conditions
Appendicitis
Interventions
Cold Therapy, Standard of Care
Device · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 22, 2026, 11:41 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Lidocaine and Esmolol to Improve the Quality of Recovery

NCT01114997
View directory record Official record
Conditions
Pain, Constipation, Nausea, Vomiting
Interventions
Lidocaine, Esmolol, Lidocaine + Esmolol (Combo)
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 22, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

NCT02096458
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
Interventions
Dexlansoprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
25 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 22, 2026, 11:41 AM EDT
Completed Phase 3 Interventional

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

NCT04157985
View directory record Official record
Conditions
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
Interventions
Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
Drug · Other
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 22, 2026, 11:41 AM EDT
Recruiting No phase listed Observational

Natural History of Noncirrhotic Portal Hypertension

NCT02417740
View directory record Official record
Conditions
Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 11:41 AM EDT
Completed Phase 4 Interventional Results available

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793
View directory record Official record
Conditions
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
Interventions
Pasireotide, Cabergoline, Pasireotide LAR
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 22, 2026, 11:41 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

NCT05875948
View directory record Official record
Conditions
Hepatorenal Syndrome, Acute Kidney Injury
Interventions
R2R01, Terlipressin
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 22, 2026, 11:41 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

NCT07109726
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Solid Tumor, Cervical Cancer
Interventions
TER-2013, Fulvestrant injection
Drug
Lead sponsor
Terremoto Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Duarte, California • Irvine, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 11:41 AM EDT
Not listed No phase listed Observational

Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders

NCT01438385
View directory record Official record
Conditions
Ampullary Cancer, Duodenal Cancer, Bile Duct Cancer, Bile Duct Disorders, Gallstones, Obstructive Jaundice, Pancreatic Disorders (Noncancerous), Colorectal Cancer, Esophageal Cancer, Barrett's Esophagus, Gastric Malignancies, Pancreatic Cancer, Pediatric Gastroenterology, Cholangiocarcinoma, Pancreatic Pseudocysts, Acute and Chronic Pancreatitis, Recurrent Pancreatitis, Cholangitis, Bile Leak, Biliary Strictures, Pancreatic Divisum, Biliary and Pancreatic Stones, Choledocholithiasis
Interventions
Interventional Endoscopy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 22, 2026, 11:41 AM EDT
Active, not recruiting No phase listed Observational

Alpha-1 Antitrypsin Deficiency Adult Liver Study

NCT02014415
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
Liver Biopsy (Biopsy Group Only)
Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 11:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study

NCT02253225
View directory record Official record
Conditions
Bipolar Disorder, Major Depression, Rumination
Interventions
Functional Magnetic Resonance Imaging (fMRI)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 22, 2026, 11:41 AM EDT
Completed Phase 1Phase 2 Interventional

Carbon Monoxide-Saturated Medium for Islet Isolation

NCT02567240
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Carbon monoxide-bubbled mediums
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 69 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 22, 2026, 11:41 AM EDT
Active, not recruiting Phase 1 Interventional

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NCT05215574
View directory record Official record
Conditions
Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer, Squamous Cell Carcinoma of Head and Neck, Bladder Urothelial Cancer, Colorectal Carcinoma, Esophageal Cancer, Ovarian Cancer, Renal Cell Carcinoma, Prostate Cancer, Melanoma, Mesothelioma, Cholangiocarcinoma
Interventions
NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Gilbert, Arizona • Los Angeles, California • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 22, 2026, 11:41 AM EDT
Completed No phase listed Observational

pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture

NCT01392274
View directory record Official record
Conditions
Cholangiocarcinoma, Bile Duct Inflammation
Interventions
Not listed
Lead sponsor
Mauna Kea Technologies
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 22, 2026, 11:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

NCT03711058
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Interventions
Copanlisib, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 22, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer

NCT02324335
View directory record Official record
Conditions
Head and Neck Neoplasms, Mucositis
Interventions
Brilacidin, Placebo
Drug · Other
Lead sponsor
Innovation Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
16
States / cities
Gilbert, Arizona • Lakeland, Florida • Columbus, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 22, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Results available

8.4% Sodium Bicarbonate Locks in Intestinal Failure

NCT05813535
View directory record Official record
Conditions
Intestinal Failure, CRBSI - Catheter Related Bloodstream Infection
Interventions
Sodium bicarb lock
Drug
Lead sponsor
Riad Rahhal
Other
Eligibility
1 Year to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 22, 2026, 11:41 AM EDT